ESR1 and breast carcinoma: Overall, 80% of breast cancers are estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative tumors, and a subset of these patients may benefit from adding adjuvant chemotherapy to their treatment regimen, potentially reducing the risk of recurrence by an additional 2–10% [2,3].